Aytu Biopharma Inc (OQ:AYTU)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 7900 E. Union Avenue, Suite 920
DENVER CO 80237
Tel: N/A
Website: https://aytubio.com
IR: See website
<
Key People
Joshua R. Disbrow
Chairman of the Board, Chief Executive Officer
Mark K. Oki
Chief Financial Officer, Treasurer, Company Secretary
Greg Pyszczymuka
Chief Commercial Officer
Business Overview
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company's Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company's prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
Financial Overview
For the six months ended 31 December 2023, Aytu Biopharma Inc revenues decreased 17% to $45M. Net loss increased 13% to $8.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects (Loss) gain on derivative warrant liabil decrease from $3.6M (income) to $6.5M (expense), Amortization of intangible assets increase of 9% to $2.6M (expense).
Employees: 150 as of Jun 30, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $12.49M as of Dec 31, 2023
Annual revenue (TTM): $98.50M as of Dec 31, 2023
EBITDA (TTM): $4.50M as of Dec 31, 2023
Net annual income (TTM): -$18.00M as of Dec 31, 2023
Free cash flow (TTM): $6.11M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 5,567,597 as of Feb 1, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.